GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Piotroski F-Score

Macrogenics (Macrogenics) Piotroski F-Score

: 2 (As of Today)
View and export this data going back to 2013. Start your Free Trial

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Macrogenics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Macrogenics's Piotroski F-Score or its related term are showing as below:

MGNX' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 2

During the past 13 years, the highest Piotroski F-Score of Macrogenics was 5. The lowest was 2. And the median was 4.


Macrogenics Piotroski F-Score Historical Data

The historical data trend for Macrogenics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 2.00 4.00 2.00

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 6.00 4.00 2.00

Competitive Comparison

For the Biotechnology subindustry, Macrogenics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Macrogenics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Macrogenics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -38.009 + 57.469 + 17.554 + -46.072 = $-9.06 Mil.
Cash Flow from Operations was -12.833 + -2.089 + -35.246 + -28.037 = $-78.21 Mil.
Revenue was 24.213 + 13.136 + 10.397 + 9.164 = $56.91 Mil.
Gross Profit was 20.69 + 11.959 + 7.038 + 9.001 = $48.69 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(280.468 + 343.498 + 305.653 + 339.972 + 298.418) / 5 = $313.6018 Mil.
Total Assets at the begining of this year (Dec22) was $280.47 Mil.
Long-Term Debt & Capital Lease Obligation was $30.20 Mil.
Total Current Assets was $251.34 Mil.
Total Current Liabilities was $56.11 Mil.
Net Income was -66.443 + -41.304 + -24.813 + 12.802 = $-119.76 Mil.

Revenue was 10.673 + 26.007 + 41.734 + 71.176 = $149.59 Mil.
Gross Profit was 10.625 + 23.605 + 38.591 + 69.385 = $142.21 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(335.245 + 271.445 + 218.043 + 195.347 + 280.468) / 5 = $260.1096 Mil.
Total Assets at the begining of last year (Dec21) was $335.25 Mil.
Long-Term Debt & Capital Lease Obligation was $30.11 Mil.
Total Current Assets was $222.18 Mil.
Total Current Liabilities was $48.61 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Macrogenics's current Net Income (TTM) was -9.06. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Macrogenics's current Cash Flow from Operations (TTM) was -78.21. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-9.058/280.468
=-0.03229602

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-119.758/335.245
=-0.35722531

Macrogenics's return on assets of this year was -0.03229602. Macrogenics's return on assets of last year was -0.35722531. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Macrogenics's current Net Income (TTM) was -9.06. Macrogenics's current Cash Flow from Operations (TTM) was -78.21. ==> -78.21 <= -9.06 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=30.196/313.6018
=0.09628771

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=30.106/260.1096
=0.11574352

Macrogenics's gearing of this year was 0.09628771. Macrogenics's gearing of last year was 0.11574352. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=251.339/56.108
=4.47955728

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=222.18/48.611
=4.57057045

Macrogenics's current ratio of this year was 4.47955728. Macrogenics's current ratio of last year was 4.57057045. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Macrogenics's number of shares in issue this year was 62.044. Macrogenics's number of shares in issue last year was 61.562. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=48.688/56.91
=0.85552627

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=142.206/149.59
=0.95063841

Macrogenics's gross margin of this year was 0.85552627. Macrogenics's gross margin of last year was 0.95063841. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=56.91/280.468
=0.20291085

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=149.59/335.245
=0.44621098

Macrogenics's asset turnover of this year was 0.20291085. Macrogenics's asset turnover of last year was 0.44621098. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+0+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Macrogenics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Macrogenics  (NAS:MGNX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Macrogenics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Macrogenics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949